UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Form 10-K ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 _____________________________________ ...

Pulse Biosciences (Nasdaq : PLSE) February 2021 Forward-looking statements This presentation by Pulse Biosciences, Inc., contain estimates and forward-looking statements as of February 3, 2021 including, among others, statements regarding Pulse Biosciences' future business plans, products, commercial applications, intellectual property strategy, clinical trials, regulatory processes and pathways, and markets for its technologies, as well as patient and physician behavior and preferences and other future eve ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2020 Results Earnings Conference Call February 22, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Vice President at Gilmartin Group LLC Darrin Uecker - Chief Executive Officer, President, Director Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandra Gardiner - Executive Vice President, Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Michael Fox - Park City Capital Operator ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - Chief Executive Officer, President and Director Ed Ebbers - Executive Vice President and General Manager, Dermatology Sandra Gardiner - Executive Vice President and Chief Financial Office Conference Call Participants Sean Kang - H.C. Wainwright Operator Greeting and welcome to the Pulse Biosciences' Third Quarter 2020 Earnings Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bio ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Philip Taylor - IR Darrin Uecker - President, CEO Ed Ebbers - EVP and General Manager of Dermatology Sandy Gardiner - EVP and CFO Conference Call Participants Sean Kang - H.C. Wainwright Operator Thank you for standing by. This is the conference operator. Welcome to the Pulse Biosciences Second Quarter 2020 Earnings Conference Call. As a reminder, all participants are in a listen-only mode ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscien ...

Financial Data and Key Metrics Changes - Operating expenses for Q1 2020 were $12 million, up from $10.4 million in the prior year, driven by expansion in operational infrastructure and clinical trial costs [49] - Net loss for Q1 2020 was $11.9 million, compared to $10.1 million in Q1 2019 [51] - Cash and cash equivalents totaled $15.9 million as of March 31, 2020, down from $25.4 million as of December 31, 2019 [51] Business Line Data and Key Metrics Changes - The company reported an increase in general and administrative expenses to $5.6 million from $4.4 million, primarily due to increased personnel [49] - Research and development expenses rose to $6.2 million from $5.8 million, also attributed to increased personnel [50] Market Data and Key Metrics Changes - The COVID-19 pandemic significantly impacted elective procedure volumes, with 92% of surveyed dermatologists reporting a reduction of at least 50% in aesthetic procedures [36] - Despite the downturn, 75% of aesthetic dermatologists indicated they are actively scheduling future procedures, reflecting optimism for a rapid recovery [38] Company Strategy and Development Direction - The company aims for regulatory clearance of the CellFX System in the U.S. and EU, with a goal to submit a 510(k) application by Q3 2020 [21][28] - Plans for commercialization in the EU are underway, with the potential to obtain CE Mark as early as Q1 2021 due to regulatory delays [26][28] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the company's prospects despite the challenges posed by COVID-19, emphasizing progress on key objectives [7][56] - The company is adapting to remote work and has implemented new workflows to maintain operations without significant disruption [10][11] Other Important Information - The company is pursuing a rights offering to raise up to $30 million, with expected net proceeds of approximately $29.5 million [52] - The rights offering is structured to allow stockholders to purchase units consisting of common stock and warrants, with no expected dilution for those who fully exercise their rights [53][54] Q&A Session Summary - No specific questions or answers were documented in the provided content, as the call concluded without a Q&A segment [60][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Pulse Bioscien ...